Also known as: CSL
CSL is a global biopharma company with a dynamic portfolio of lifesaving medicines, including treatments for hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. The company says it started in 1916 in Australia and later became listed on the Australian Securities Exchange.
Eli Lilly has acquired rights to CSL's IL-6 inhibitor clazakizumab in a $100 million deal, expanding its cardiometabolic pipeline. The monoclonal antibody targets chronic inflammation, particularly in cardiovascular conditions. This move follows Lilly's successful obesity and diabetes drugs that drove $65.1 billion in 2025 revenue.
Regulatory incentives for rare disease treatments, including market exclusivity and development subsidies, are spurring pharmaceutical innovation across the US, Europe, Japan, and Australia, with multiple companies advancing therapies for conditions affecting limited patient populations.
CSL Limited has licensed global development and commercialization rights for clazakizumab to Eli Lilly outside of ESKD-related cardiovascular risk. CSL receives $100 million upfront and retains rights to the ESKD indication.
CSL Seqirus announced that neffy adrenaline nasal spray has been approved in Australia for emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over, marking the first new adrenaline administration method approved in over 30 years.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01759849 |
Effect of in Vitro Blocking the Common Beta Chain on Cell Viability in Asthma |
COMPLETED | |
| NCT01632852 |
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission |
COMPLETED | PHASE1 |
| NCT01499420 |
A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients |
COMPLETED | PHASE2 |
| NCT01281774 |
A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT01129661 |
Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT00680446 |
Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency |
COMPLETED | PHASE3 |
| NCT00405184 |
Ig NextGen 10% in Patients With Primary Immune Deficiency (PID) |
COMPLETED | PHASE3 |
| NCT00401739 |
Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia |
COMPLETED | PHASE1 |
| NCT00391131 |
Subcutaneous Ig NextGen 16% in PID Patients |
COMPLETED | PHASE3 |
| NCT00362349 |
Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients |
COMPLETED | PHASE3 |
